Vanda Pharmaceuticals Inc. (VNDA) › Net IncomeVanda Pharmaceuticals Inc. (VNDA) — Net IncomeAnnual figures by period end, from SEC filings.2009-12-31: -$35.86M2010-12-31: $7.19M2011-12-31: -$9.80M2012-12-31: -$28.62M2013-12-31: -$21.05M2014-12-31: $20.19M2015-12-31: -$39.87M2016-12-31: -$18.01M2017-12-31: -$15.57M2018-12-31: $25.21M2019-12-31: $115.55M2020-12-31: $23.34M2021-12-31: $33.15M2022-12-31: $6.28M2023-12-31: $2.51M2024-12-31: -$18.90M2025-12-31: -$220.47M-$220.47M2009-12-31Net Income (USD)2025-12-31Period endedNet IncomeChange YoYSource filing2025-12-31-$220.47M—2026-02-12From 2025-01-012024-12-31-$18.90M-853.3%2026-02-12From 2024-01-012023-12-31$2.51M-60.0%2026-02-12From 2023-01-012022-12-31$6.28M-81.1%2025-02-14From 2022-01-012021-12-31$33.15M+42.1%2024-02-08From 2021-01-012020-12-31$23.34M-79.8%2023-02-09From 2020-01-012019-12-31$115.55M+358.4%2022-02-24From 2019-01-012018-12-31$25.21M—2021-02-11From 2018-01-012017-12-31-$15.57M—2020-02-26From 2017-01-012016-12-31-$18.01M—2019-02-19From 2016-01-012015-12-31-$39.87M-297.5%2018-02-15From 2015-01-012014-12-31$20.19M—2017-02-17From 2014-01-012013-12-31-$21.05M—2016-02-12From 2013-01-012012-12-31-$28.62M—2015-03-13From 2012-01-012011-12-31-$9.80M-236.3%2014-02-25From 2011-01-012010-12-31$7.19M—2013-02-26From 2010-01-012009-12-31-$35.86M—2012-03-09From 2009-01-01Other metrics: RevenueCost of RevenueGross ProfitOperating IncomeEPS (Diluted)Total AssetsTotal LiabilitiesShareholders' EquityCash & EquivalentsOperating Cash FlowCapital ExpendituresShares OutstandingDividends Per ShareWeighted Average Diluted SharesEPS (Basic)